{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:22:22Z","timestamp":1786119742444,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/bor.0b013e328344fddb","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T00:08:36Z","timestamp":1300838916000},"page":"282-287","source":"Crossref","is-referenced-by-count":50,"title":["Update 2011: leflunomide in rheumatoid arthritis \u2013 strengths and weaknesses"],"prefix":"10.1097","volume":"23","author":[{"given":"Frank","family":"Behrens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Koehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1124\/dmd.109.027482","article-title":"Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A771726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis","volume":"37","author":"Grabar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/ard.2008.099093","article-title":"Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis","volume":"68","author":"Grabar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00228-010-0916-0","article-title":"Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.","volume":"67","author":"Kim","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3899\/jrheum.090874","article-title":"Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice","volume":"37","author":"Foeldvari","year":"2010","journal-title":"J Rheumatol"},{"issue":"Suppl II","key":"R6-12-20210128","first-page":"523","article-title":"Safety and efficacy of leflunomide in addition to ongoing methotrexate therapy in psoriatic arthritis a subgroup analysis of the OSPAL study","volume":"67","author":"Behrens","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/030097401300162897","article-title":"Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine","volume":"30","author":"Larsen","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00296-008-0682-9","article-title":"Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis","volume":"29","author":"Pfeil","year":"2009","journal-title":"Rheumatol Int"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/03009740802360632","article-title":"Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis","volume":"38","author":"Lee","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicentre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-009-1349-y","article-title":"Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha","volume":"29","author":"De Stefano","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00296-009-1302-z","article-title":"Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis","volume":"30","author":"Henes","year":"2010","journal-title":"Rheumatol Int"},{"issue":"Suppl II","key":"R16-12-20210128","first-page":"90","article-title":"Combination rituximab and leflunomide produces lasting responses in rheumatoid arthritis","volume":"67","author":"Vital","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"R17-12-20210128","first-page":"76","article-title":"Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) or leflunomide (LEF) in the German RTX treatment of active rheumatoid arthritis (RA) in daily practice trial","volume":"68","author":"Wendler","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","article-title":"Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing","volume":"32","author":"Alcorn","year":"2009","journal-title":"Drug Saf"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/rheumatology\/keq301","article-title":"Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.","volume":"50","author":"Strangfeld","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1593\/neo.10168","article-title":"Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention","volume":"12","author":"Hail","year":"2010","journal-title":"Neoplasia"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/1535-7163.MCT-08-0664","article-title":"Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells","volume":"8","author":"Baumann","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(04)15969-2","article-title":"Interstitial lung disease and disease modifying antirheumatic drugs","volume":"363","author":"Scott","year":"2004","journal-title":"Lancet"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/kep164","article-title":"Editorial. Leflunomide and the lung","volume":"48","author":"Kelly","year":"2009","journal-title":"Rheumatology"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","article-title":"Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sawada","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/rheumatology\/kep050","article-title":"Clinical expression of leflunomide-induced pneumonitis","volume":"48","author":"Chikura","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/RHU.0b013e3181c3f87e","article-title":"Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy","volume":"15","author":"Wong","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/rheumatology\/kep227","article-title":"Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sato","year":"2009","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e328344fddb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:04:38Z","timestamp":1786043078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201105000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328344fddb","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}